This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Enhabit (EHAB) 주식 개요
는 미국에서 재택 의료 및 호스피스 서비스를 제공합니다. 자세히 보기
EHAB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Enhabit, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$13.80 |
| 52주 최고가 | US$14.22 |
| 52주 최저가 | US$6.47 |
| 베타 | 0.96 |
| 1개월 변동 | 0.51% |
| 3개월 변동 | 23.66% |
| 1년 변동 | 29.70% |
| 3년 변동 | 16.06% |
| 5년 변동 | n/a |
| IPO 이후 변동 | -44.80% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Apr 24
EHAB: Kinderhook Cash Offer And Deal Completion Will Shape Forward Risk Balance
Analysts have aligned Enhabit’s updated fair value estimate with the agreed Kinderhook Industries takeout price, trimming the target by $0.03 to $13.80 as they factor in the all cash $13.80 per share acquisition and modest tweaks to growth, margin and discount rate assumptions. Analyst Commentary Street research has largely converged around Enhabit’s agreed takeout price, with multiple firms resetting ratings and targets to align with the US$13.80 per share all cash offer from Kinderhook Industries.내러티브 업데이트 • Apr 10
EHAB: Cash Sale Terms And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have inched their average price target for Enhabit up by about $0.03 to roughly $13.83, reflecting recent research that aligns estimates with the agreed all cash acquisition price of $13.80 per share. Analyst Commentary Recent research on Enhabit has shifted quickly after the announced all cash acquisition at $13.80 per share, with most commentary now centered on how closely the stock aligns with the agreed deal value rather than on long term standalone upside.내러티브 업데이트 • Mar 26
EHAB: Kinderhook Cash Deal And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have adjusted Enhabit’s price target to $13.80 per share, in line with the agreed all cash acquisition price from Kinderhook Industries. They cite the pending takeout and recent shifts in ratings to Hold, Neutral, Perform and Market Perform at multiple firms as the key drivers of this update.Recent updates
내러티브 업데이트 • Apr 24
EHAB: Kinderhook Cash Offer And Deal Completion Will Shape Forward Risk Balance
Analysts have aligned Enhabit’s updated fair value estimate with the agreed Kinderhook Industries takeout price, trimming the target by $0.03 to $13.80 as they factor in the all cash $13.80 per share acquisition and modest tweaks to growth, margin and discount rate assumptions. Analyst Commentary Street research has largely converged around Enhabit’s agreed takeout price, with multiple firms resetting ratings and targets to align with the US$13.80 per share all cash offer from Kinderhook Industries.내러티브 업데이트 • Apr 10
EHAB: Cash Sale Terms And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have inched their average price target for Enhabit up by about $0.03 to roughly $13.83, reflecting recent research that aligns estimates with the agreed all cash acquisition price of $13.80 per share. Analyst Commentary Recent research on Enhabit has shifted quickly after the announced all cash acquisition at $13.80 per share, with most commentary now centered on how closely the stock aligns with the agreed deal value rather than on long term standalone upside.내러티브 업데이트 • Mar 26
EHAB: Kinderhook Cash Deal And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have adjusted Enhabit’s price target to $13.80 per share, in line with the agreed all cash acquisition price from Kinderhook Industries. They cite the pending takeout and recent shifts in ratings to Hold, Neutral, Perform and Market Perform at multiple firms as the key drivers of this update.내러티브 업데이트 • Mar 10
EHAB: Kinderhook Cash Takeout And Sector Reimbursement Trends Will Shape Forward Risk Balance
The analyst price target for Enhabit has been adjusted from $13.08 to $13.80. Analysts cite the agreed all-cash acquisition by Kinderhook Industries at $13.80 per share as the primary reference point for the valuation.Seeking Alpha • Feb 25
Enhabit: Why This Healthcare Buyout Won't Raise FTC Alarms
Summary Enhabit Inc. is being acquired by Kinderhook Industries for $13.80 per share, an all-cash deal at an enterprise valuation of $1.1 billion. I see minimal antitrust risk, as Kinderhook lacks significant overlap in hospice care, making regulatory intervention unlikely. EHAB trades at a discount to peers due to higher debt and inconsistent profitability, but the acquisition premium reflects limited market optimism. With only a 1.8% spread to the deal price and limited upside, I rate EHAB a Hold pending deal completion. Read the full article on Seeking Alpha내러티브 업데이트 • Feb 24
EHAB: Takeout At 13.80 And Reimbursement Clarity Will Shape Forward Risk Balance
The analyst price target for Enhabit has been raised from $11.75 to $13.08. Analysts cited the agreed all-cash acquisition at $13.80 per share and related updates to assumed future P/E as the key drivers of the change.내러티브 업데이트 • Feb 08
EHAB: Clearer Reimbursement And Mixed Ratings Will Shape Forward Risk Balance
Narrative Update on Enhabit The analyst price target for Enhabit has moved to $11.75. Analysts note that clearer home health reimbursement rules, an improved regulatory backdrop, and what they describe as a discounted valuation support a more constructive stance on the shares.내러티브 업데이트 • Jan 25
EHAB: Clearer Reimbursement And Mixed Ratings Will Shape Future Earnings Visibility
Narrative Update The analyst price target for Enhabit has shifted from $10.60 to $11.75, as analysts factor in an improved home health reimbursement backdrop, clearer earnings visibility, and reduced regulatory overhang reflected in recent upgrades and higher targets around $12. Analyst Commentary Recent research on Enhabit has turned more positive, with several firms lifting ratings and price targets to around US$12 as the regulatory picture for home health reimbursement becomes clearer.내러티브 업데이트 • Jan 10
EHAB: Final Rule Clarity And Mixed Ratings Will Shape Earnings Outlook
Analysts have lifted their price expectations for Enhabit, with our fair value estimate moving from US$9.38 to US$10.60. They point to greater earnings clarity following the final home health rule, a modest adjustment to discount rates and profit assumptions, and recent research that highlights both improving operations and what some see as a discounted valuation.내러티브 업데이트 • Aug 08
Aging Demographics Will Fuel US Home Care Expansion
Despite a notable improvement in net profit margin and a lower future P/E ratio, the consensus analyst price target for Enhabit has been reduced from $10.00 to $9.38. What's in the News Enhabit, Inc.분석 기사 • Jul 03
Enhabit, Inc. (NYSE:EHAB) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Enhabit, Inc. ( NYSE:EHAB ) shareholders won't be pleased to see that the share price has had a very rough month...분석 기사 • Jun 14
Enhabit (NYSE:EHAB) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...새로운 내러티브 • May 29
US Home Health Demand And Value-Based Care Will Create Future Opportunities
Structural trends and targeted expansion in underserved markets are driving sustained revenue growth and building a reliable recurring revenue base.분석 기사 • May 09
Returns On Capital At Enhabit (NYSE:EHAB) Paint A Concerning Picture
When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...분석 기사 • Apr 09
Enhabit, Inc.'s (NYSE:EHAB) Revenues Are Not Doing Enough For Some Investors
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...Seeking Alpha • Feb 03
Enhabit: Healthcare Predictive Analytics, FCF, Very Undervalued
Summary EHAB's investments in healthcare predictive analytics, expected to grow at 23%-24% CAGR, could significantly boost future net income growth. Restructuring, activism, and strategic reviews are potential catalysts for stock price appreciation, enhancing financial flexibility from 2025 to 2030. Despite recent negative net income, EHAB's consistent positive cash flow and undervaluation indicate substantial upside potential in stock price. Valuation models suggest higher upside potential, with best case scenario implying a target price of $11-$12 per share. Read the full article on Seeking Alpha분석 기사 • Dec 14
Is Enhabit (NYSE:EHAB) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Nov 07
Returns On Capital At Enhabit (NYSE:EHAB) Paint A Concerning Picture
If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...분석 기사 • Jul 17
Is Enhabit (NYSE:EHAB) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Jul 15
Is Enhabit Dead? Not Quite Yet
Summary It is soon to be the last independent home health and hospice company. Scarcity value could drive interest from financial and strategic bidders. Shareholders have a slate of new directors to refresh the company. Read the full article on Seeking Alpha분석 기사 • Jun 19
Enhabit (NYSE:EHAB) Could Be At Risk Of Shrinking As A Company
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...분석 기사 • May 10
An Intrinsic Calculation For Enhabit, Inc. (NYSE:EHAB) Suggests It's 42% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Enhabit fair value estimate is US$14.19 Enhabit is estimated...분석 기사 • Mar 09
Here's What Analysts Are Forecasting For Enhabit, Inc. (NYSE:EHAB) After Its Annual Results
It's been a pretty great week for Enhabit, Inc. ( NYSE:EHAB ) shareholders, with its shares surging 17% to US$10.34 in...분석 기사 • Mar 05
The Market Doesn't Like What It Sees From Enhabit, Inc.'s (NYSE:EHAB) Revenues Yet
You may think that with a price-to-sales (or "P/S") ratio of 0.4x Enhabit, Inc. ( NYSE:EHAB ) is a stock worth checking...분석 기사 • Feb 09
Enhabit (NYSE:EHAB) Could Be Struggling To Allocate Capital
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...주주 수익률
| EHAB | US Healthcare | US 시장 | |
|---|---|---|---|
| 7D | 0.07% | -0.4% | 0.8% |
| 1Y | 29.7% | 31.5% | 20.6% |
수익률 대 산업: EHAB은 지난 1년 동안 31.5%의 수익을 기록한 US Healthcare 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: EHAB은 지난 1년 동안 20.6%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| EHAB volatility | |
|---|---|
| EHAB Average Weekly Movement | 6.6% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: EHAB는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: EHAB의 주간 변동성(7%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1998 | 10,800 | Barb Jacobsmeyer | www.ehab.com |
는 미국에서 재택 의료 및 호스피스 서비스를 제공합니다. 홈 헬스 부문에서는 간호, 물리, 작업, 언어 치료, 의료 및 사회 복지, 가정 건강 보조 서비스를 제공합니다. 또한 환자 교육, 통증 관리, 상처 관리 및 드레싱 교체, 심장 재활, 주입 요법, 약물 투여, 숙련된 관찰 및 평가 서비스도 제공합니다; 당뇨병, 고혈압, 관절염, 알츠하이머병, 시력 저하, 척추 협착증, 파킨슨병, 골다공증, 복합 상처 관리, 만성 통증 등 만성 질환 및 질환 치료와 당뇨병, 울혈성 심부전, 정형외과 수술 또는 부상 후, 호흡기 질환 환자를 위한 질환별 계획; 환자의 건강 관련 문제로 인해 발생하는 재정, 개인, 사회적 문제에 대해 환자와 가족을 위한 상담도 제공합니다.
Enhabit, Inc. 기초 지표 요약
| EHAB 기초 통계 | |
|---|---|
| 시가총액 | US$706.91m |
| 순이익 (TTM) | -US$3.20m |
| 매출 (TTM) | US$1.06b |
0.7x
주가매출비율(P/S)-220.9x
주가수익비율(P/E)EHAB는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| EHAB 손익계산서 (TTM) | |
|---|---|
| 매출 | US$1.06b |
| 매출원가 | US$544.20m |
| 총이익 | US$520.70m |
| 기타 비용 | US$523.90m |
| 순이익 | -US$3.20m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.062 |
| 총이익률 | 48.90% |
| 순이익률 | -0.30% |
| 부채/자본 비율 | 72.7% |
EHAB의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/16 17:18 |
| 종가 | 2026/05/14 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Enhabit, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Joanna Sylvia Gajuk | BofA Global Research |
| Jason Cassorla | Citigroup Inc |
| Jamie Perse | Goldman Sachs |